A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance

Rigel Pharmaceuticals (RIGL) recently issued full year 2026 guidance, indicating anticipated total revenue of about US$275 ...

Rigel Provides Business Update and 2026 Outlook

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
American Association of Individual Investors

Why Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Down 5.01%

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio

LOUISVILLE, Ky., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Onco360 ®, the nation’s leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as limited distribution specialty pharmacy ...

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with ...
Benzinga.com

What to Expect from Rigel Pharmaceuticals's Earnings

Rigel Pharmaceuticals RIGL will release its quarterly earnings report on Tuesday, 2025-08-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Rigel Pharmaceuticals ...
Zacks.com on MSN

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.
Investing

Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...
Seeking Alpha

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, ...
Business Insider

Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific ...
Reuters

U.S. FDA approves Rigel Pharma's treatment for a type of leukemia

Dec 1 (Reuters) - Rigel Pharmaceuticals (RIGL.O), opens new tab said on Thursday the U.S. health regulator has approved its drug for the treatment of patients with a type of leukemia, sending its ...

Onco360(R) Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio

Onco360(R) , the nation's leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as limited distribution specialty pharmacy partner for TAVALISSE(R) (fostamatinib disodium ...